Urothelial carcinoma is cancer of the urinary system. The urothelium is a kind of epithelial (protective) lining of the urinary system, which includes the urinary tract, bladder, your ureters (the ...

First-line treatment with disitamab vedotin and toripalimab improved outcomes over chemotherapy in patients with HER2-expressing, locally advanced or metastatic urothelial carcinoma.

Over the past decade, immunotherapy has fundamentally reshaped the therapeutic landscape for several urological cancers, this mostly involved urothelial ...

The median duration of response was 9.2 months. The combination of atezolizumab and split doses of cisplatin and gemcitabine can produce durable responses in patients with locally advanced or ...

Impaired renal function and cisplatin-based regimens as risk factors for neoadjuvant chemotherapy-induced acute kidney injury in muscle-invasive bladder cancer: A multicenter retrospective study. This ...

Multiple therapeutic options are available for the management of patients with upper urinary tract transitional cell carcinoma (TCC). Radical nephroureterectomy with an ipsilateral bladder cuff is the ...

In the exploratory subgroup analysis of chRCC by PD-L1 CPS status, there was a trend favoring nivolumab plus ipilimumab for ...

Cluster 4/5 was treated with the dual ICI regimen of ipilimumab plus nivolumab. This arm remains open to accrual. Clusters 3, 6, and 7 were excluded from the study. Additional secondary endpoints are ...

Jelmyto shows long-term effectiveness in treating low-grade, upper tract urothelial carcinoma, with a high complete response rate in the OLYMPUS trial. The median duration of response for patients ...